Risk Management

OMIC Digest Archives 2022

OMIC Digest: Vol. 32 | No. 1 | 2022

  • Feature: Giant Cell Arteritis: Delayed diagnosis and treatment
  • Eye on OMICBoard changes and a new Chair announced for 2023
  • Policy IssuesLiability and coverage for patient falls
  • Closed Claim StudyFailure to diagnose Giant Cell Arteritis results in settlement
  • Risk Management RemediesWhat’s in your toolbox?
  • < click to view or download


Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.